Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evogliptin in Calcific Aortic Valve Disease
NCT04055883Phase 2Completed
- Sponsor
- Dong-A ST
- Start
- Aug 2019
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DA5221-B2 in calcific aortic valve disease (CAVD), sponsored by Dong-A ST. Started Aug 2019; status: completed.
02
Drugs
DA5221-B2
03
Conditions
calcific aortic valve disease (CAVD)
Beyond the preview
Go deeper on NCT04055883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04055883.